Licogliflozin

Cat. No.: HY-109092

CAS No.: 1291094-73-9

Molecular Formula: $C_{23}H_{28}O_7$

Molecular Weight: 416.46

Target: SGLT

Pathway: Membrane Transporter/Ion Channel

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (240.12 mM; Need ultrasonic)

H_2O : 2 mg/mL (4.80 mM; Need ultrasonic)

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	2.4012 mL	12.0060 mL	24.0119 mL
5 mM	0.4802 mL	2.4012 mL	4.8024 mL
10 mM	0.2401 mL	1.2006 mL	2.4012 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (6.00 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (6.00 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Licogliflozin is a sodium glucose cotransporter (SGLT1 and SGLT2) inhibitor.

IC_{50} & Target

SGLT1, SGLT2[1]

In Vitro

Licogliflozin (LIK066) is a non-anti-fibrotic treatment agent for non-alcoholic steatohepatitis (NASH).

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Monica A. Konerman, et al. Overview of Clinical Treatment Trials for NASH.Curr Hepatol Rep. 2017 Dec;16(4): 366-373.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA